Cibc World Market Inc. Purchases 5,550 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Cibc World Market Inc. raised its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENEGet Rating) by 13.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,887 shares of the biopharmaceutical company’s stock after acquiring an additional 5,550 shares during the period. Cibc World Market Inc. owned about 0.09% of Xenon Pharmaceuticals worth $1,426,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of XENE. DekaBank Deutsche Girozentrale grew its position in Xenon Pharmaceuticals by 9.7% in the first quarter. DekaBank Deutsche Girozentrale now owns 12,400 shares of the biopharmaceutical company’s stock valued at $373,000 after acquiring an additional 1,100 shares during the period. Arizona State Retirement System grew its holdings in shares of Xenon Pharmaceuticals by 4.5% during the first quarter. Arizona State Retirement System now owns 11,156 shares of the biopharmaceutical company’s stock worth $341,000 after purchasing an additional 477 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Xenon Pharmaceuticals by 89.1% during the first quarter. Victory Capital Management Inc. now owns 14,264 shares of the biopharmaceutical company’s stock worth $403,000 after purchasing an additional 6,719 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Xenon Pharmaceuticals by 41.7% during the first quarter. Russell Investments Group Ltd. now owns 73,919 shares of the biopharmaceutical company’s stock worth $2,258,000 after purchasing an additional 21,748 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in shares of Xenon Pharmaceuticals by 42.0% during the first quarter. New York State Common Retirement Fund now owns 11,500 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 3,400 shares during the last quarter. 91.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

XENE has been the topic of several research analyst reports. Royal Bank of Canada increased their target price on Xenon Pharmaceuticals from $46.00 to $49.00 and gave the stock an “outperform” rating in a report on Tuesday, October 11th. Wedbush upped their price target on Xenon Pharmaceuticals from $41.00 to $50.00 in a research note on Wednesday, August 10th. Raymond James initiated coverage on Xenon Pharmaceuticals in a research note on Tuesday, October 18th. They set an “outperform” rating and a $52.00 price target on the stock. Guggenheim cut their price target on Xenon Pharmaceuticals from $53.00 to $49.00 and set a “buy” rating on the stock in a research note on Friday, November 11th. Finally, Bank of America initiated coverage on Xenon Pharmaceuticals in a research note on Monday, August 29th. They set a “buy” rating and a $45.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $49.43.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $34.32 on Friday. Xenon Pharmaceuticals Inc. has a 1-year low of $23.26 and a 1-year high of $41.39. The business’s 50-day moving average price is $36.08 and its two-hundred day moving average price is $33.83.

Xenon Pharmaceuticals Profile

(Get Rating)

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.

See Also

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENEGet Rating).

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.